Advancement and Challenges in Multiple Sclerosis: Understanding the Disease from Etiology to Treatment.

IF 1.7
Kamal Kant Ravi, Kunal Arora
{"title":"Advancement and Challenges in Multiple Sclerosis: Understanding the Disease from Etiology to Treatment.","authors":"Kamal Kant Ravi, Kunal Arora","doi":"10.2174/0115672026468062260824061821","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple Sclerosis (MS) is a chronic immune-mediated neurodegenerative disorder of the Central Nervous System (CNS) that affects more than 2.8 million people worldwide. It is recognized as one of the leading causes of non-traumatic neurological disability among young adults. It is an inflammatory demyelination disease with axonal damage and progressive neurological disability, which creates high personal, social, and economic costs. The development of neuroimaging, immunobiology, and molecular biology has significantly enhanced the accuracy of diagnosis, disease monitoring, and therapeutic development, enabling earlier intervention and better relapse management with disease-modifying therapeutic agents. These innovations have improved clinical training, retention, and optimization of treatment for relapsing forms of the disease. The Pathophysiology of MS is complex, and the factors that lead to the condition are a complicated interplay of genetic risk, environmental exposure (Epstein-Barr virus, vitamin D deficiency, and smoking), and impaired immunological responses. Despite these gains, there are some significant limitations. There are limited therapeutic interventions that are effective against progressive multiple sclerosis; remyelination failure still plays a role in irreversible disability. Predicting treatment response in this disorder is yet to be identified. The existing literature has identified gaps in understanding immune dysregulation, neurodegeneration, and new modulators, including viral exposures, the gut microbiota, and cell signalling pathways. These unaddressed gaps impede the design of individual and neuroprotective therapeutic approaches that can modify the disease course over the long term. This review critically examines the recent developments and current issues in multiple sclerosis, including etiology and Pathophysiology and diagnostic and therapeutic interventions, with a particular focus on highlighting critical areas of knowledge gaps as well as future research directions that may be used in support of multidisciplinary and integrative approaches to enhance the quality of life and multiple sclerosis clinical outcomes in patients.</p>","PeriodicalId":93965,"journal":{"name":"Current neurovascular research","volume":" ","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current neurovascular research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115672026468062260824061821","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Multiple Sclerosis (MS) is a chronic immune-mediated neurodegenerative disorder of the Central Nervous System (CNS) that affects more than 2.8 million people worldwide. It is recognized as one of the leading causes of non-traumatic neurological disability among young adults. It is an inflammatory demyelination disease with axonal damage and progressive neurological disability, which creates high personal, social, and economic costs. The development of neuroimaging, immunobiology, and molecular biology has significantly enhanced the accuracy of diagnosis, disease monitoring, and therapeutic development, enabling earlier intervention and better relapse management with disease-modifying therapeutic agents. These innovations have improved clinical training, retention, and optimization of treatment for relapsing forms of the disease. The Pathophysiology of MS is complex, and the factors that lead to the condition are a complicated interplay of genetic risk, environmental exposure (Epstein-Barr virus, vitamin D deficiency, and smoking), and impaired immunological responses. Despite these gains, there are some significant limitations. There are limited therapeutic interventions that are effective against progressive multiple sclerosis; remyelination failure still plays a role in irreversible disability. Predicting treatment response in this disorder is yet to be identified. The existing literature has identified gaps in understanding immune dysregulation, neurodegeneration, and new modulators, including viral exposures, the gut microbiota, and cell signalling pathways. These unaddressed gaps impede the design of individual and neuroprotective therapeutic approaches that can modify the disease course over the long term. This review critically examines the recent developments and current issues in multiple sclerosis, including etiology and Pathophysiology and diagnostic and therapeutic interventions, with a particular focus on highlighting critical areas of knowledge gaps as well as future research directions that may be used in support of multidisciplinary and integrative approaches to enhance the quality of life and multiple sclerosis clinical outcomes in patients.

多发性硬化症的进展与挑战:从病因到治疗的认识。
多发性硬化症(MS)是一种慢性免疫介导的中枢神经系统(CNS)神经退行性疾病,影响全球280多万人。它被认为是年轻人非创伤性神经功能障碍的主要原因之一。它是一种炎症性脱髓鞘疾病,伴有轴突损伤和进行性神经功能障碍,造成很高的个人、社会和经济成本。神经影像学、免疫生物学和分子生物学的发展显著提高了诊断、疾病监测和治疗的准确性,使早期干预和更好的疾病修饰治疗药物复发管理成为可能。这些创新改进了临床培训,保留和优化治疗复发形式的疾病。多发性硬化症的病理生理是复杂的,导致这种疾病的因素是遗传风险、环境暴露(eb病毒、维生素D缺乏和吸烟)和免疫反应受损的复杂相互作用。尽管取得了这些进展,但仍存在一些重大的局限性。对进行性多发性硬化症有效的治疗干预有限;髓鞘再生失败仍在不可逆转的残疾中起作用。预测这种疾病的治疗反应尚未确定。现有文献已经确定了在理解免疫失调、神经退行性变和新的调节剂(包括病毒暴露、肠道微生物群和细胞信号通路)方面的空白。这些未解决的差距阻碍了个体和神经保护治疗方法的设计,这些方法可以长期改变疾病的进程。本文回顾了多发性硬化症的最新进展和当前问题,包括病因学和病理生理学以及诊断和治疗干预,特别关注强调知识空白的关键领域以及未来的研究方向,这些方向可能用于支持多学科和综合方法,以提高多发性硬化症患者的生活质量和临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书